WeeklyLevels's profile picture. Weekly charts + known catalysts. Invalidation first. Not advice.

Small Cap Ben

@WeeklyLevels

Weekly charts + known catalysts. Invalidation first. Not advice.

Vertex has been such a consistent performer in a sea of volatility. Their cystic fibrosis franchise is a fortress. Now, can they deliver on their pipeline? $VRTX


It's not just about the science; it's about the addressable market. A cure for a super-rare disease might not be a great investment if only 100 people have it. #MarketSize #TAM


It's easy to get discouraged, but remember that every major medical breakthrough started as a risky, speculative biotech venture. #Perspective #Medicine


I'm convinced half of biotech trading is just trying to guess what a vague press release about "positive topline data" actually means. #Investing #Biotech


I'm keeping an eye on Crispr Therapeutics. The first-ever CRISPR-based therapy approval was a historic moment. Now they have to execute commercially. $CRSP


Interest rates have a huge impact on biotech valuations. When rates are high, it's tough for these cash-burning companies. A pivot from the Fed would be jet fuel for the sector. #Fed #InterestRates


Watching Moderna try to find its next act after the COVID vaccine has been an interesting case study. Proving their mRNA platform works for other diseases is key. $MRNA


The whole concept of personalized medicine is fascinating. Companies that can tailor treatments to an individual's genetic makeup are the ones I'm watching. #Genomics #PersonalizedMedicine


The best time to buy biotech is when everyone else hates it. The sentiment was in the gutter for two years, and those who bought then are sitting pretty now. #Contrarian #BuyLow


I'm not a scientist, but I try to understand the basic mechanism of action for any drug I invest in. It helps separate the plausible from the far-fetched. #Research


For anyone tracking, XBI is up big since its April lows.[2] It's been a quiet rally, but a ~30% move is hard to ignore. Definitely keeping this trend on my main screen. #XBI #Investing


You can't ignore the big secular trends that could boost XBI long-term: an aging population, chronic diseases, and the need for next-gen therapies. #XBI #SecularTrends


If this XBI uptrend holds, the next catalyst will be M&A. Big pharma companies have a lot of cash and looming patent cliffs, making acquisitions likely.[1][4][5] #XBI #DealFlow


The path higher for XBI won't be a straight line. I'm expecting plenty of pullbacks and choppy trading as the sector finds its footing. #XBI #Volatility


Many of the companies inside XBI are all-or-nothing bets. A good trial result can send a stock soaring, which is what makes this ETF so explosive. #XBI #Catalyst


The equal-weight setup of XBI is its secret sauce.[8][9] It means a handful of small and mid-cap companies can really move the needle, getting more attention than they would in a market-cap weighted fund.[10]


XBI is up more than 9% in the last month alone, crushing the broader indexes.[1] That's the kind of outperformance that gets you noticed.


XBI’s rebound isn't just technical. The fundamentals seem to be getting better too—funding is picking up and trial data has been encouraging. #XBI #Fundamentals


If the market starts rotating into sectors that have been ignored for a while, XBI is a prime candidate to benefit from those flows. #XBI #Rotation


The comeback in XBI seems to be driven by a renewed belief in the drug pipelines. The risk/reward balance is starting to look attractive again. #XBI #Investing


Loading...

Something went wrong.


Something went wrong.